News
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Fourth Quarter and Year Ended September 30, 2019
ESSA Pharma Presents Data on EPI-7386 at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
ESSA Announces Changes to its Board of Directors
ESSA Pharma Board of Directors Approves Stock Option Plan RSU Plan and Option Grants
ESSA Pharma Presents New Data on EPI-7386 at the European Society of Medical Oncology (ESMO) 2019 Congress
ESSA to Present at Ladenburg Thalmann Healthcare Conference
ESSA Pharma to Present at H.C. Wainwright 21st Annual Global Investment Conference
ESSA Pharma Completes Public Offering and Concurrent Private Placement for Aggregate Gross Process of US$36 Million
ESSA Pharma Announces $36 Million Public Offering of Common Stock and Concurrent Private Placement
ESSA Pharma Provides Corporate Update and Reports Financial Results for the Fiscal Third Quarter Ended June 20, 2019